8-K current report · filed Jul 30, 2026

AVANOS MEDICAL, INC. (AVNS) 8-K Current Report: July 30, 2026

Item 1.02Item 3.01Item 3.03Item 5.01Item 5.03Item 7.01Item EX-99.1Item 2.03Item 1.01Item 5.02Item 2.01AVNS overview

Short answer

AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 3.01 (Notice of Delisting), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation), Item 1.01 (Entry into a Material Definitive Agreement), Item 5.02 (Departure/Election of Directors or Officers), Item 2.01 (Completion of Acquisition or Disposition of Assets). $675.0M initial term loan borrowed at closing, materially increasing AVANOS’ leverage and interest burden.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

AVANOS MEDICAL, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $675.0M initial term loan borrowed at closing, materially increasing AVANOS’ leverage and interest burden
  • $100.0M delayed-draw term commitments available for 24 months, providing additional acquisition or liquidity capacity
  • $100.0M revolving facility, with borrowings priced at base rate plus 2.50% or SOFR plus 3.50%
  • Loans mature July 27, 2033, while term-loan SOFR margins range from 4.75% to 5.25%
  • Debt secured by substantially all borrower and guarantor assets, with mandatory prepayments and financial covenants limiting flexibility

Item 1.02 · Termination of a Material Definitive Agreement

  • Legacy June 24, 2022 credit agreement fully repaid and terminated at merger closing
  • Replacement Credit Agreement entered concurrently, indicating post-merger refinancing of existing debt facilities
  • JPMorgan Chase Bank served as administrative agent under the terminated facility

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Merger completed, converting Avanos shares into $25.00 cash per share
  • Approximately $1,200 million paid to Avanos stockholders, eliminating future public-market equity participation
  • Parent funded the acquisition through equity contributions and debt financing under a credit agreement
  • Equity awards canceled and settled in cash, with performance awards based on specified achievement levels
  • Options priced above $25.00 received no consideration, limiting employee award value to in-the-money options

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 links the new financial obligation to the transaction described in Item 1.01
  • Investor impact depends on Item 1.01 terms, including obligation amount, pricing, maturity and use of proceeds

Item 3.01 · Notice of Delisting

  • AVNS trading suspended before market open July 27, 2026 following merger completion
  • NYSE delisting removes Common Stock from public exchange trading
  • Form 25 requested to terminate NYSE listing and Section 12(b) registration
  • Form 15 planned to deregister shares and suspend SEC reporting obligations

Item 3.03 · Material Modification to Rights of Security Holders

  • Merger effective time eliminated existing Avanos common-stockholder rights
  • Former shareholders entitled only to merger consideration under the Merger Agreement
  • Avanos shares no longer carry ongoing ownership, voting, or economic rights post-merger

Item 5.01 · Changes in Control of Registrant

  • Merger completion triggered a change in control of Avanos Medical
  • Avanos became a wholly owned subsidiary of Parent
  • Public shareholders’ ownership and governance influence ended following the merger

Item 5.02 · Departure/Election of Directors or Officers

  • Merger-effective board turnover: six incumbent directors resigned, indicating complete governance transition to the acquiring parent
  • David C. Pacitti appointed CEO and director, consolidating executive and board leadership under the post-merger structure
  • Scott M. Galovan appointed CFO, Treasurer, and director, establishing continuity in financial leadership after closing
  • John S. Fischer appointed General Counsel and Secretary, succeeding to expanded legal and corporate-governance responsibilities
  • All pre-merger officers removed at the Effective Time, making post-closing management appointments material to execution and oversight

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Certificate of incorporation and bylaws replaced entirely at merger closing
  • Governance documents now mirror Merger Subsidiary’s pre-closing forms
  • Changes reflect merger completion and may reset shareholder rights and corporate governance terms

Item 7.01 · Regulation FD Disclosure

  • Merger closing announced jointly by Avanos Medical and Parent
  • Transaction completion shifts focus to integration, ownership, and post-merger financial reporting
  • Exhibit 99.1 contains the substantive closing details and investor-relevant terms

Item EX-99.1 · Exhibit EX-99.1

  • AIP completed Avanos acquisition for approximately $1.272 billion, converting the company into a privately held business
  • Avanos shareholders received $25.00 cash per share under the merger agreement
  • Avanos common stock ceased trading on the New York Stock Exchange upon closing
  • CEO Dave Pacitti remains in place, supporting continuity during AIP’s operational improvement strategy

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other AVANOS MEDICAL, INC. 8-K filings

Get the next AVNS 8-K as it lands

Follow AVNS for push alerts, or ask the research agent what this filing means.